Affordable Access

Publisher Website

Protease-Activated Receptors 1 and 3 are Differentially Expressed on Human Monocyte Subsets and are Upregulated by Lipopolysaccharide Ex Vivo and In Vivo.

  • Thaler, Barbara1
  • Hohensinner, Philipp J1
  • Baumgartner, Johanna1
  • Haider, Patrick1
  • Krychtiuk, Konstantin A1
  • Schörgenhofer, Christian2
  • Jilma, Bernd2
  • Hell, Lena3
  • Fischer, Michael B4, 5
  • Huber, Kurt6
  • Hengstenberg, Christian1
  • Speidl, Walter S1
  • Wojta, Johann1, 7, 8
  • 1 Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. , (Austria)
  • 2 Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. , (Austria)
  • 3 Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria. , (Austria)
  • 4 Clinic for Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria. , (Austria)
  • 5 Department for Health Science and Biomedicine, Danube University Krems, Krems, Austria. , (Austria)
  • 6 3rd Medical Department for Cardiology and Emergency Medicine, Wilhelminen Hospital, Vienna, Austria. , (Austria)
  • 7 Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria. , (Austria)
  • 8 Core Facilities, Medical University of Vienna, Vienna, Austria. , (Austria)
Published Article
Thrombosis and Haemostasis
Georg Thieme Verlag KG
Publication Date
Sep 01, 2019
DOI: 10.1055/s-0039-1692219
PMID: 31291665


Monocytes are activated in inflammatory conditions via a variety of cytokine receptors as well as in a procoagulatory setting through thrombin, acting upon protease-activated receptors (PARs). This study investigated the expression pattern of PAR1 and PAR3 on human monocyte subsets. Furthermore, a possible regulation of the expression of PAR1 and PAR3 in these cells by inflammatory activation were studied. CD16+ monocytes showed significantly higher levels of PAR1 and PAR3 as compared with CD16- monocytes. Ex vivo treatment of whole blood with lipopolysaccharide (LPS) increased PAR1 and PAR3 messenger ribonucleic acid (mRNA) in human monocytes. In addition, increase of PAR1 was seen in all three subsets upon LPS treatment, whereas PAR3 increased significantly only in CD16- monocytes and nonclassical CD16+ monocytes. Protein levels of PAR1 and PAR3 significantly increased on monocytes in vivo in human endotoxemia 1 hour after LPS infusion. PAR1 increased significantly in CD16- monocytes and nonclassical CD16+ monocytes. In this in vivo model, PAR3 was also significantly elevated in CD16- monocytes and increased slightly albeit not significantly in CD16+ monocytes. Endotoxemia increased plasminogen activator inhibitor-1 (PAI-1) and tissue factor (TF) expression in monocytes in humans. Pretreatment of healthy volunteers with the PAR1 antagonist vorapaxar blocked the increase in PAI-1 but not the increase in TF. We here provide new evidence for a critical role for monocytes as cellular mediators that contribute to the activation of coagulation in diseases characterized by an inflammatory state. Georg Thieme Verlag KG Stuttgart · New York.

Report this publication


Seen <100 times